Innovation Pharmaceuticals Inc. Company Review & Valuation IPIX
About Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. The company's lead drug compound is Brilacidin, which is in Phase II study for the treatment of oral mucositis, inflammatory bowel disease, and acute bacterial skin and skin structure infection. It also develops Prurisol, a Phase IIb compound, which is in development for psoriasis; and Kevetrin, a lead anti-cancer compound for treating ovarian cancer. In addition, the company owns other candidates for treating diseases, including autism, arthritis, asthma, MS/ALS/Parkinson's, cancer, hypertensive emergency, and bacterial and fungal infections. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Beverly, Massachusetts.
- Beverly, Massachusetts
Primary Stock Exchange Listings